Please login to the form below

Not currently logged in
Email:
Password:

Elan and Wyeth limit Alzheimer's trial

Irish biotech Elan and partner Wyeth have removed the highest dose of potential Alzheimer's therapy bapineuzumab from phase III trials

Irish biotech Elan and partner Wyeth have removed the highest dose of potential Alzheimer's therapy bapineuzumab from phase III trials.

The companies will discontinue trials of 2.0mg/kg of bazineuzumab in two ongoing phase III trials in patients with mild-to-moderate Alzheimer's disease (AD) who do not carry the Apolipoprotein E4 allele. However, trials of 0.5mg/kg and 1.0mg/kg will continue as planned.

The decision to discontinue the higher dose was made following a review of vasogenic edema, an accumulation of water in the brain, by the study's independent Safety Monitoring Committee (SMC).

Two further studies, testing a dose of 0.5mg/kg in patients who are carriers of the Apolipoprotein E4 allele are unaffected by this decision.

Elan president Dr Carlos Paya said: "Our review of the safety data and the feedback from the Safety Monitoring Committee made it clear that continued development of the highest dose was not advisable. The decision to remove the highest dose from development reduces risk to patients and it also helps to reduce risk to the overall development effort."

The global bapineuzumab phase III programme consists of four randomised, double-blind, placebo-controlled studies involving approximately 4,000 patients.

2nd April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics